LYVA Labs, in partnership with Innovate UK and a consortium of internationally recognised scientific, technical, and commercial experts, is proud to launch the Innovate UK Biomedical Catalyst Accelerator – Future Medicines.
The Biomedical Catalyst is Innovate UK’s flagship grant funding mechanism, designed to accelerate innovation and help UK companies bring products to market more efficiently.
Biomedical Catalyst Accelerators help SMEs, spinouts, and academic innovators develop and test innovative health and care solutions across therapeutics, medical devices, diagnostics, and digital health. Through thematic Accelerators, participants gain tailored support to refine their ideas, explore market viability, and prepare for clinical or commercial validation.
-
- UK-based SMEs (as defined by Innovate UK).
- Academics in the early stages of forming an SME
- Start-ups developing innovations within the scope of Future Medicines addressing clear and evidenced healthcare challenges.
- At early-stage Technology Readiness Levels, typically TRL 2-4
- Companies with technologies, products, processes, or services that have a commercial route to market.
- Organisations working in radiopharmaceuticals innovation particularly encouraged.
-
This accelerator is for companies involved in the development, discovery or manufacturing of a broad range of next-generation medical treatments, technologies, products, processes, or services to address increasingly complex diseases, usually leveraging advanced scientific approaches for more targeted, effective therapies tailored to individual patient needs.
Examples include (but are not restricted to) the fields below. We are particularly interested in applicants working in Radiopharmaceuticals.
- Radiopharmaceuticals
- Microbiome and Phage-based therapies
- Biopharmaceuticals
- Regenerative and Personalised Medicines
- Gene therapies and CAR-T cell therapies
- Antimicrobial resistance
-
Pre-Accelerator (Nov 2025 – Dec 2025):
Companies will build a strong foundation in drug discovery, development, regulation, market strategy, and exploitation planning, with guidance on grants, early-stage financing, and investment readiness – while establishing a peer network.Accelerator (Jan 2026 –Mar 2026):
A select group from the Pre-Accelerator will receive tailored technical, scientific, and commercial support, a detailed R&D and exploitation plan, support to draft grant applications, investor pitch training, sector-specific introductions, and a personalised pack to support future funding. -
- World-leading expertise in drug discovery, development, and regulation
- Market research, competitive analysis, and commercial strategy support
- Investment readiness training, pitch preparation, and funding guidance
- Support to draft a grant application
Access to cutting-edge research facilities and networking with sector experts - The opportunity to work with partners to develop technical roadmaps
- Face-to-face peer and investor events
-
Any queries about the Future Medicines accelerator should be sent to futuremedicines.accelerator@lyvalabs.com
Innovate UK held an informative webinar introducing the Innovate UK Biomedical Catalyst Accelerators programme on 3 Sept: click here to watch the recording and download the slides.
The Biomedical Catalyst team also held live events in London 9 September, Liverpool 11 September and Glasgow 15 September. Read more about the roadshows and download the event slides, covering all five Biomedical Catalyst Accelerators (Femtech, Future Medicines, Hospital to Community, Medtech Ventures and Chronic Conditions).
For queries about each specific accelerator, contact the team who are running it. You can also contact the Biomedical Catalyst team.
